211 related articles for article (PubMed ID: 31847589)
1. αKlotho attenuates cardiac hypertrophy and increases myocardial fibroblast growth factor 21 expression in uremic rats.
Suassuna PGA; Cherem PM; de Castro BB; Maquigussa E; Cenedeze MA; Lovisi JCM; Custódio MR; Sanders-Pinheiro H; de Paula RB
Exp Biol Med (Maywood); 2020 Jan; 245(1):66-78. PubMed ID: 31847589
[TBL] [Abstract][Full Text] [Related]
2. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.
Law JP; Price AM; Pickup L; Radhakrishnan A; Weston C; Jones AM; McGettrick HM; Chua W; Steeds RP; Fabritz L; Kirchhof P; Pavlovic D; Townend JN; Ferro CJ
J Am Heart Assoc; 2020 Apr; 9(7):e016041. PubMed ID: 32212912
[TBL] [Abstract][Full Text] [Related]
3. Paricalcitol downregulates myocardial renin-angiotensin and fibroblast growth factor expression and attenuates cardiac hypertrophy in uremic rats.
Freundlich M; Li YC; Quiroz Y; Bravo Y; Seeherunvong W; Faul C; Weisinger JR; Rodriguez-Iturbe B
Am J Hypertens; 2014 May; 27(5):720-6. PubMed ID: 24072555
[TBL] [Abstract][Full Text] [Related]
4. The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.
Grabner A; Faul C
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):314-24. PubMed ID: 27219043
[TBL] [Abstract][Full Text] [Related]
5. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.
Xie J; Yoon J; An SW; Kuro-o M; Huang CL
J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745
[TBL] [Abstract][Full Text] [Related]
6. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.
Hu MC; Shi M; Cho HJ; Adams-Huet B; Paek J; Hill K; Shelton J; Amaral AP; Faul C; Taniguchi M; Wolf M; Brand M; Takahashi M; Kuro-O M; Hill JA; Moe OW
J Am Soc Nephrol; 2015 Jun; 26(6):1290-302. PubMed ID: 25326585
[TBL] [Abstract][Full Text] [Related]
7. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy.
Xie J; Wu YL; Huang CL
Vitam Horm; 2016; 101():311-30. PubMed ID: 27125747
[TBL] [Abstract][Full Text] [Related]
8. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.
Carrillo-López N; Panizo S; Alonso-Montes C; Román-García P; Rodríguez I; Martínez-Salgado C; Dusso AS; Naves M; Cannata-Andía JB
Kidney Int; 2016 Jul; 90(1):77-89. PubMed ID: 27165819
[TBL] [Abstract][Full Text] [Related]
9. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia.
Mace ML; Gravesen E; Nordholm A; Hofman-Bang J; Secher T; Olgaard K; Lewin E
Kidney Int; 2017 Jul; 92(1):165-178. PubMed ID: 28341272
[TBL] [Abstract][Full Text] [Related]
10. Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
Slavic S; Ford K; Modert M; Becirovic A; Handschuh S; Baierl A; Katica N; Zeitz U; Erben RG; Andrukhova O
Sci Rep; 2017 Sep; 7(1):11298. PubMed ID: 28900153
[TBL] [Abstract][Full Text] [Related]
11. Fgf21 is required for cardiac remodeling in pregnancy.
Redondo-Angulo I; Mas-Stachurska A; Sitges M; Tinahones FJ; Giralt M; Villarroya F; Planavila A
Cardiovasc Res; 2017 Nov; 113(13):1574-1584. PubMed ID: 28472473
[TBL] [Abstract][Full Text] [Related]
12. A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy.
Bao JF; Hu PP; She QY; Li A
J Am Soc Nephrol; 2020 Jul; 31(7):1423-1434. PubMed ID: 32527977
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.
Czaya B; Seeherunvong W; Singh S; Yanucil C; Ruiz P; Quiroz Y; Grabner A; Katsoufis C; Swaminathan S; Abitbol C; Rodriguez-Iturbe B; Faul C; Freundlich M
Am J Hypertens; 2019 Jan; 32(1):34-44. PubMed ID: 30329020
[TBL] [Abstract][Full Text] [Related]
14. High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic rats.
Bisson SK; Ung RV; Picard S; Valade D; Agharazii M; Larivière R; Mac-Way F
J Bone Miner Metab; 2019 Mar; 37(2):212-223. PubMed ID: 29603070
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor-21 protects against fibrosis in hypertensive heart disease.
Ferrer-Curriu G; Redondo-Angulo I; Guitart-Mampel M; Ruperez C; Mas-Stachurska A; Sitges M; Garrabou G; Villarroya F; Fernández-Solà J; Planavila A
J Pathol; 2019 May; 248(1):30-40. PubMed ID: 30582148
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Growth Factor 23 and Klotho in AKI.
Christov M; Neyra JA; Gupta S; Leaf DE
Semin Nephrol; 2019 Jan; 39(1):57-75. PubMed ID: 30606408
[TBL] [Abstract][Full Text] [Related]
17. Klotho Lacks an FGF23-Independent Role in Mineral Homeostasis.
Andrukhova O; Bayer J; Schüler C; Zeitz U; Murali SK; Ada S; Alvarez-Pez JM; Smorodchenko A; Erben RG
J Bone Miner Res; 2017 Oct; 32(10):2049-2061. PubMed ID: 28600880
[TBL] [Abstract][Full Text] [Related]
18. Effect of Continuous Intravenous Calcium Loading on Fibroblast Growth Factor 23 in Normal and Uremic Rats.
Shikida Y; Mizobuchi M; Inoue T; Hamada T; Ogata H; Koiwa F; Shibata T
Calcif Tissue Int; 2018 Oct; 103(4):455-464. PubMed ID: 29882057
[TBL] [Abstract][Full Text] [Related]
19. αKlotho and Chronic Kidney Disease.
Neyra JA; Hu MC
Vitam Horm; 2016; 101():257-310. PubMed ID: 27125746
[TBL] [Abstract][Full Text] [Related]
20. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway.
Ding J; Tang Q; Luo B; Zhang L; Lin L; Han L; Hao M; Li M; Yu L; Li M
Eur J Pharmacol; 2019 Sep; 859():172549. PubMed ID: 31325434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
